Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Where Procore Technologies Stands With Analysts
Procore Technologies (NYSE:PCOR) has observed the following analyst ratings within the last quarter:
Goldman Sachs Maintains Neutral on Procore Technologies, Lowers Price Target to $77
Goldman Sachs maintains Procore Technologies (NYSE:PCOR) with a Neutral and lowers the price target from $90 to $77.
What 4 Analyst Ratings Have To Say About Procore Technologies
Within the last quarter, Procore Technologies (NYSE:PCOR) has observed the following analyst ratings:
Mizuho Initiates Coverage On Procore Technologies with Buy Rating, Announces Price Target of $75
Mizuho analyst Matthew Broome initiates coverage on Procore Technologies (NYSE:PCOR) with a Buy rating and announces Price Target of $75.
Insider Weekends: ICONIQ Adds To Its Stake In Construction Management Software Company Procore Technologies + Notable Insider Trades
The huge drop we saw in most markets earlier this week triggered a large number of insider purchases and it was interesting to watch both the S&P 500 and the Nasdaq close in positive territory for the week.
Procore Announced Expansion Into France
Procore Technologies, Inc. (NYSE: PCOR), a leading global provider of construction management software, today announces its launch in France as part of continued global expansion and growth.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows.
Piper Sandler Maintains Overweight on Procore Technologies, Lowers Price Target to $100
Piper Sandler analyst Brent Bracelin maintains Procore Technologies (NYSE:PCOR) with a Overweight and lowers the price target from $115 to $100.